ASC-话题@MedSci

#ASC#

1352篇内容 | 3978人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1939053, encodeId=cfb619390534b, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出, objectType=article, longId=194255, objectId=475f19425533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=475f19425533, replyNumber=0, likeNumber=57, createdTime=2020-09-27, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=475f19425533, moduleTitle=ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=475f19425533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939137, encodeId=d631193913e99, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021：固定剂量的Durvalumab单药治疗尿道肿瘤具有良好的安全性（STRONG研究）, objectType=article, longId=207176, objectId=9c2020e176f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2020e176f1, replyNumber=0, likeNumber=59, createdTime=2021-06-10, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2020e176f1, moduleTitle=ASCO GU 2021：固定剂量的Durvalumab单药治疗尿道肿瘤具有良好的安全性（STRONG研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2020e176f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939054, encodeId=66941939054af, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, objectType=article, longId=194315, objectId=4a69194315ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a69194315ed, replyNumber=0, likeNumber=65, createdTime=2020-09-03, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a69194315ed, moduleTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a69194315ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939085, encodeId=37bf19390854d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%, objectType=article, longId=195492, objectId=c5e419549231, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e419549231, replyNumber=0, likeNumber=94, createdTime=2020-08-15, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e419549231, moduleTitle=ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e419549231)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939088, encodeId=5d31193908844, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=2020 ASCO年会：短程放疗为晚期直肠癌患者带来新获益, objectType=article, longId=195629, objectId=b50d19562969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b50d19562969, replyNumber=0, likeNumber=74, createdTime=2021-04-13, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b50d19562969, moduleTitle=2020 ASCO年会：短程放疗为晚期直肠癌患者带来新获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b50d19562969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939108, encodeId=0c161939108fc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相, objectType=article, longId=201031, objectId=6a33201031d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a33201031d1, replyNumber=0, likeNumber=124, createdTime=2021-05-12, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a33201031d1, moduleTitle=ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a33201031d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939124, encodeId=59141939124dc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Circulation：鱼油Vascepa可大大降低血运重建需求！, objectType=article, longId=205345, objectId=c2cf2053456b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2cf2053456b, replyNumber=0, likeNumber=90, createdTime=2021-02-20, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2cf2053456b, moduleTitle=Circulation：鱼油Vascepa可大大降低血运重建需求！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2cf2053456b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939044, encodeId=651219390448b, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=JACC Cardiovasc Interv：英国研究称肺动脉去神经治疗肺动脉高压安全有效！, objectType=article, longId=193138, objectId=6b26193138ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b26193138ff, replyNumber=0, likeNumber=65, createdTime=2021-02-11, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b26193138ff, moduleTitle=JACC Cardiovasc Interv：英国研究称肺动脉去神经治疗肺动脉高压安全有效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b26193138ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939096, encodeId=6afd19390962d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Circ：Cardiovasc Inte：经导管主动脉瓣置换术后心衰再入院的决定因素及其影响, objectType=article, longId=198141, objectId=0a5319814153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a5319814153, replyNumber=0, likeNumber=80, createdTime=2020-10-01, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a5319814153, moduleTitle=Circ：Cardiovasc Inte：经导管主动脉瓣置换术后心衰再入院的决定因素及其影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a5319814153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939144, encodeId=5cae1939144a9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）, objectType=article, longId=207205, objectId=96bf20e20583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96bf20e20583, replyNumber=0, likeNumber=77, createdTime=2021-09-23, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96bf20e20583, moduleTitle=ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96bf20e20583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939134, encodeId=4c2919391344c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）, objectType=article, longId=207162, objectId=89d220e162b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89d220e162b5, replyNumber=0, likeNumber=66, createdTime=2021-09-07, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89d220e162b5, moduleTitle=ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89d220e162b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939042, encodeId=ea7a193904203, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Res: 亚洲新冠患者用ACEI/ARB获益或更大！欧洲高血压学会工作组发文, objectType=article, longId=192659, objectId=324719265976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=324719265976, replyNumber=0, likeNumber=78, createdTime=2020-09-12, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=324719265976, moduleTitle=Cardiovasc Res: 亚洲新冠患者用ACEI/ARB获益或更大！欧洲高血压学会工作组发文, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=324719265976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939082, encodeId=ab7a193908226, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, objectType=article, longId=195300, objectId=951f1953003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=951f1953003d, replyNumber=0, likeNumber=61, createdTime=2021-01-07, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=951f1953003d, moduleTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=951f1953003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939083, encodeId=2cdb19390831a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, objectType=article, longId=195301, objectId=db5919530147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db5919530147, replyNumber=0, likeNumber=100, createdTime=2020-06-11, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db5919530147, moduleTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db5919530147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939081, encodeId=8581193908109, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020丨遗憾！早期局部治疗未能改善原发IV期乳腺癌女性的总生存率, objectType=article, longId=195299, objectId=c885195299eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c885195299eb, replyNumber=0, likeNumber=0, createdTime=2020-10-27, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c885195299eb, moduleTitle=ASCO 2020丨遗憾！早期局部治疗未能改善原发IV期乳腺癌女性的总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c885195299eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939119, encodeId=97c11939119f5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Ann Vasc Surg：AIA或CIAA血管内修复术中IBSG植入系统是IIA保存安全且有效的技术, objectType=article, longId=203340, objectId=e689203340db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e689203340db, replyNumber=0, likeNumber=66, createdTime=2021-04-23, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e689203340db, moduleTitle=Ann Vasc Surg：AIA或CIAA血管内修复术中IBSG植入系统是IIA保存安全且有效的技术, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e689203340db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939127, encodeId=8e5d193912ea9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：Apabetone治疗对急性冠脉综合征合并2型糖尿病患者心衰住院风险的影响, objectType=article, longId=205644, objectId=d7f2205644a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7f2205644a9, replyNumber=0, likeNumber=67, createdTime=2021-02-19, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7f2205644a9, moduleTitle=Cardiovasc Diabetol：Apabetone治疗对急性冠脉综合征合并2型糖尿病患者心衰住院风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7f2205644a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939084, encodeId=dbbf19390843a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020 | 无处不在的曲妥珠单抗, objectType=article, longId=195360, objectId=5fa919536006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fa919536006, replyNumber=0, likeNumber=78, createdTime=2021-03-16, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fa919536006, moduleTitle=ASCO 2020 | 无处不在的曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fa919536006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939073, encodeId=d67319390e3e9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=2020 ASCO 消化道领域重磅研究新近进展大盘点！, objectType=article, longId=195133, objectId=f804195133d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f804195133d0, replyNumber=0, likeNumber=54, createdTime=2021-01-15, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f804195133d0, moduleTitle=2020 ASCO 消化道领域重磅研究新近进展大盘点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f804195133d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939078, encodeId=00e219390e832, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相, objectType=article, longId=195229, objectId=29d0195229fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29d0195229fb, replyNumber=0, likeNumber=61, createdTime=2021-02-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29d0195229fb, moduleTitle=ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29d0195229fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASC

2020-05-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出

2020-09-27

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021：固定剂量的Durvalumab单药治疗尿道肿瘤具有良好的安全性（STRONG研究）

2021-06-10

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期

2020-09-03

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%

2020-08-15

quxin068 (审核中...)

前往app查看评论内容

#ASC#

2020 ASCO年会：短程放疗为晚期直肠癌患者带来新获益

2021-04-13

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相

2021-05-12

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Circulation：鱼油Vascepa可大大降低血运重建需求！

2021-02-20

quxin068 (审核中...)

前往app查看评论内容

#ASC#

JACC Cardiovasc Interv：英国研究称肺动脉去神经治疗肺动脉高压安全有效！

2021-02-11

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Circ：Cardiovasc Inte：经导管主动脉瓣置换术后心衰再入院的决定因素及其影响

2020-10-01

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）

2021-09-23

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）

2021-09-07

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Res: 亚洲新冠患者用ACEI/ARB获益或更大！欧洲高血压学会工作组发文

2020-09-12

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！

2021-01-07

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位

2020-06-11

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020丨遗憾！早期局部治疗未能改善原发IV期乳腺癌女性的总生存率

2020-10-27

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Ann Vasc Surg：AIA或CIAA血管内修复术中IBSG植入系统是IIA保存安全且有效的技术

2021-04-23

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：Apabetone治疗对急性冠脉综合征合并2型糖尿病患者心衰住院风险的影响

2021-02-19

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020 | 无处不在的曲妥珠单抗

2021-03-16

quxin068 (审核中...)

前往app查看评论内容

#ASC#

2020 ASCO 消化道领域重磅研究新近进展大盘点！

2021-01-15

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相

2021-02-24

科室
- - 订阅+
  - 更多科室
工具
服务